| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | Dividendenbekanntmachungen (15.06.2026) | 4.441 | wallstreetONLINE (Dividenden) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) A&W FOOD SERVICES OF CANADA INC CA0002251027 0,48 CAD 0,2966 EUR AEGON LTD ADR US0076CA1045 0,2468 USD 0,2134 EUR AGROB IMMOBILIEN... ► Artikel lesen | |
| Mo | Nurix, BioNxt Solutions, Zealand Pharma - Neue Therapien sorgen für Fantasie | 492 | inv3st.de | Der Biotech-Sektor erlebt derzeit eine Phase enormer Dynamik. Besonders Therapien gegen Adipositas, Diabetes, Autoimmunerkrankungen und neurologische Leiden zählen zu den größten Wachstumsmärkten im... ► Artikel lesen | |
| Mo | Lifecore Biomedical, Inc.: Lifecore Biomedical Signs New Agreement with Global Pharmaceutical Company | 307 | GlobeNewswire (Europe) | --Agreement Supports Tech Transfer and Commercial Manufacturing of Currently Marketed Neurology Product-- --Seventh Addition to Lifecore's Late-Stage Pipeline in Seven Months-- CHASKA, Minn., June... ► Artikel lesen | |
| Mo | Precigen, Inc: Precigen Gains Advantage as PAPZIMEOS Granted Orphan Drug Exclusivity by FDA; Long-Term Data From Clinical Study Encouraging | 277 | ACCESS Newswire | Meg Flippin, Benzinga Staff WriterData reviewed by Dr. Helen Sabzevari at last week's Goldman Sachs healthcare conference suggests potential of extended surgical holidays for patients with RRP, a rare... ► Artikel lesen | |
| Mo | Ergebnisse der zulassungsrelevanten Phase-3-Studie "frontMIND" von Incyte zur Kombination von Tafasitamab (Monjuvi /Minjuvi ), die auf der Plenarsitzung des Kongresses der European Hematology Association (EHA) 2026 vorgestellt wurden... | 266 | Business Wire | frontMIND-Studie zur Bewertung von Tafasitamab (Monjuvi /Minjuvi bei Patienten mit zuvor unbehandeltem diffusem großzelligem B-Zell-Lymphom (DLBCL) und hochgradigem B-Zell-Lymphom (HGBL) wurde für... ► Artikel lesen | |
| Mo | Incyte gibt auf der EHA 2026 neue positive Daten bekannt, wonach INCA033989 bei Patienten mit Myelofibrose und essenzieller Thrombozythämie schnelle, robuste und anhaltende klinische und molekulare Reaktionen erzielte und gut vertragen wurde | 233 | Business Wire | Bei der Myelofibrose (MF) zeigte INCA033989 sowohl als Monotherapie als auch in Kombination mit Ruxolitinib schnelle und anhaltende klinische Vorteile, darunter eine signifikante Verringerung... ► Artikel lesen | |
| Mo | Alkermes plc: Alkermes Announces Orphan Drug Designations for Alixorexton in the U.S. and Europe | 206 | Business Wire | Alkermes plc (Nasdaq: ALKS) today announced that alixorexton, a novel, investigational, oral, selective orexin 2 receptor (OX2R) agonist in development for the treatment of narcolepsy type 1 (NT1)... ► Artikel lesen | |
| Mo | Immuneering Corporation: Immuneering Appoints Andrew Gengos as Chief Financial Officer | 200 | GlobeNewswire (Europe) | - Former CFO of Terns Pharmaceuticals to join Immuneering - - Seasoned public company CFO strengthens team with over 25 years of leadership in biotech - NEW YORK, June 15, 2026 (GLOBE NEWSWIRE) --... ► Artikel lesen | |
| Mo | Neurocrine Reports Positive Two-Year Phase 3 Data For Crenessity In Pediatric CAH | 195 | AFX News | WASHINGTON (dpa-AFX) - Neurocrine Biosciences Inc. (NBIX) on Monday reported positive two-year data from its Phase 3 CAHtalyst Pediatric study of Crenessity in children and adolescents with... ► Artikel lesen | |
| Mo | Grifols, S.A.: Grifols Launches FESILTY (fibrinogen, human-chmt) in the U.S. | 154 | GlobeNewswire (Europe) | The new fibrinogen concentrate, approved in the U.S. for acute bleeding episodes in pediatric and adult patients with congenital fibrinogen deficiency, is now available in the U.S.FESILTY complements... ► Artikel lesen | |
| Mo | Neumora Therapeutics, Inc.: Neumora Therapeutics Reports Data from Phase 3 KOASTAL Program and Provides Business and Pipeline Update | 131 | GlobeNewswire (Europe) | Navacaprant did not achieve the primary endpoint in KOASTAL-2 or -3; Company to discontinue development of navacaprant Advancing potential best-in-class programs with NMRA-511 in Alzheimer's disease... ► Artikel lesen | |
| 05:22 | Milliarden-Übernahmen, Kapitalmangel und Stammzelltherapien: Warum Mesoblast in einem spannenden Marktumfeld agiert | Small- & Micro Cap Investment | |||
| Mo | Inhibrx Biosciences, Inc.: Inhibrx Announces U.S. FDA Acceptance of BLA for Ozekibart in Patients with Conventional Chondrosarcoma | 126 | PR Newswire | No filing review issues identified by FDA with PDUFA goal date set for April 14, 2027
If Approved, Ozekibart Would Be the First and Only FDA-Approved Treatment... ► Artikel lesen | |
| Mo | Halozyme Therapeutics, Inc.: Halozyme Confirms It Projects Zero to Minimal Impact to Royalty Revenue Through At Least 2035 Based on Newly Released Draft Medicare Drug Price Negotiation Program Proposed Rule for IPAY 2029 | 124 | PR Newswire | SAN DIEGO, June 15, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company") today confirmed that the Company expects zero... ► Artikel lesen | |
| Mo | IDEAYA Biosciences, Inc.: IDEAYA Biosciences Announces IDE892, a Potential Best-in-Class MTA-Cooperative PRMT5 Inhibitor, Initiates a Phase 1/2 Clinical Combination Study in MTAP-Deleted Pancreatic and Lung Cancers | 115 | PR Newswire | IDE892 is a potential best-in-class MTA-Cooperative PRMT5 combination partner with MAT2A and pan-RAS inhibitors, with favorable drug-like properties
IDE892 has... ► Artikel lesen |
| Unternehmen / Aktien | Kurs | Dividende 12M | Div.-Rendite | Erw. Dividende | Erw. Ex.-Datum | |
|---|---|---|---|---|---|---|
| ROYALTY PHARMA | 47,055 | 0,77 | +1,64 % | 0,24 | 15.05.2026 | |
| IONIS PHARMACEUTICALS | 63,12 | 0,00 | 0,00 % | |||
| BIOGEN | 170,64 | 0,00 | 0,00 % | |||
| VERA THERAPEUTICS | 34,190 | 0,00 | 0,00 % | |||
| LENZ THERAPEUTICS | 6,645 | 0,00 | 0,00 % |
| Aktien WKN | Akt. Kurs Vortag | +/- % | Zeit | ||
|---|---|---|---|---|---|
| 10X GENOMICS INC A2PPQJ Tradegate | 27,440 24,925 | -0,380 -1,37 % | 15.06. | ||
| 4D MOLECULAR THERAPEUTICS INC A2PS5P NASDAQ | 9,210 8,830 | -0,010 -0,11 % | 15.06. | ||
| AARDVARK THERAPEUTICS INC A412BL NASDAQ | 3,850 3,890 | +0,010 +0,26 % | 15.06. | ||
| ABCELLERA BIOLOGICS INC A2QKXS Tradegate | 4,495 4,525 | -0,040 -0,88 % | 15.06. | ||
| ABIVAX SA ADR A3EWCP Tradegate | 84,000 83,50 | -1,00 -1,18 % | 15.06. | ||
| ABSCI CORPORATION A3CVW3 NASDAQ | 7,270 6,800 | 0,000 0,00 % | 15.06. | ||
| AC IMMUNE SA A2AR5F Tradegate | 2,050 2,010 | +0,025 +1,23 % | 15.06. | ||
| ACADIA PHARMACEUTICALS INC 603035 Tradegate | 18,260 18,230 | -0,090 -0,49 % | 15.06. | ||
| ACLARIS THERAPEUTICS INC A1412H Tradegate | 3,790 3,738 | +0,022 +0,58 % | 15.06. | ||
| ADAPTIVE BIOTECHNOLOGIES CORPORATION A2PLR5 Tradegate | 14,990 15,200 | -0,080 -0,53 % | 15.06. |